Frag' FlorenceEvidenz. Klar. Anwendbar.
Uhr 7/8Sources Journal Tree
Easy Demo

Lokaler Crossref-Datenbestand · journal-article

Recalcitrant folliculitis decalvans treated with baricitinib or upadacitinib: a case series

Miguel Antonio Lasheras-Pérez, Rodolfo David Palacios-Diaz, Alejandro Lobato-Berezo, Ricardo Ruiz-Villaverde, Rocío Gil-Redondo, Conrad Pujol-Marco, Mercedes Rodríguez-Serna, Antonio Sahuquillo-Torralba, Kristen I Lo Sicco, Jerry Shapiro, David Saceda-Corralo, Botella-Estrada Rafael

Clinical and Experimental Dermatology · 2026

Vollständiger Abstract

Worum geht es in dieser Arbeit?

A multicenter retrospective study of eleven patients with folliculitis decalvans treated with oral JAK inhibitors (baricitinib or upadacitinib) is reported. Disease stabilization, together with reductions in pustules, crusts, perifollicular erythema, and perifollicular hyperkeratosis, was observed following treatment.

Bibliografischer Nachweis

Publikationsdaten

Autor:innen
Miguel Antonio Lasheras-Pérez, Rodolfo David Palacios-Diaz, Alejandro Lobato-Berezo, Ricardo Ruiz-Villaverde, Rocío Gil-Redondo, Conrad Pujol-Marco, Mercedes Rodríguez-Serna, Antonio Sahuquillo-Torralba, Kristen I Lo Sicco, Jerry Shapiro, David Saceda-Corralo, Botella-Estrada Rafael
Quelle
Clinical and Experimental Dermatology
Publikation
2026-01-01
Band / Ausgabe
Nicht angegeben
Seiten
Nicht angegeben
ISSN / ISBN
0307-6938, 1365-2230
Zitationen
0 laut Crossref
Referenzen
0 hinterlegt

Zitieren

Zitierfähiger Nachweis

Miguel Antonio Lasheras-Pérez, Rodolfo David Palacios-Diaz, Alejandro Lobato-Berezo, Ricardo Ruiz-Villaverde, Rocío Gil-Redondo, Conrad Pujol-Marco, Mercedes Rodríguez-Serna, Antonio Sahuquillo-Torralba, Kristen I Lo Sicco, Jerry Shapiro, David Saceda-Corralo, Botella-Estrada Rafael (2026). Recalcitrant folliculitis decalvans treated with baricitinib or upadacitinib: a case series. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llag370
RIS BibTeX CSL-JSON

Kontext

Themen, Förderung und Nutzung

Lizenzhinweise: Lizenz 1